|
Match
|
Document |
Document Title |
|
|
7390490 |
Uses of anti-CX3CR1 antibody, anti-fractalkine antibody and fractalkine
There are provided uses of an antibody directed to CX3CR1 and fractalkine. Killer lymphocytes can be readily identified, eliminated and separated by using an anti-CX3CR1 antibody. Further, there...
|
|
|
7387776 |
Human monoclonal antibodies against CD30
Isolated human monoclonal antibodies which bind to CD30 (e.g., human CD30) are disclosed. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of...
|
|
|
7387271 |
Immunostimulatory combinations
The present invention provides immunostimulatory combinations. Generally, the immunostimulatory combinations include a TLR agonist and a TNF/R agonist. Certain immunostimulatory combinations also...
|
|
|
7384633 |
Human type antihuman IgE receptor antibody and fragment
An antibody or an antibody fragment is provided that is efficacious for treating allergic diseases in which IgE is involved. A human antibody and a fragment thereof to a receptor (FcεRI) having...
|
|
|
7371382 |
Methods of inhibiting αvβ3-mediated binding with αvβ3-specific antibodies
The invention provides enhanced LM609 grafted antibodies exhibiting selective binding affinity to α V β 3 , or a functional fragment thereof. The invention also provides nucleic acid molecules...
|
|
|
7364734 |
Treatment of LFA-1 associated disorders with increasing doses of LFA-1 antagonist
A method is provided for reducing the occurrence of fever, headache, nausea and/or vomiting associated with administration of a therapeutic compound to a mammal in need thereof, comprising...
|
|
|
7361345 |
Anti-CD40 antibodies capable of blocking B-cell activation
Methods for preventing or treating an antibody-mediated disease in a patient are presented, the methods comprising administration of a monoclonal antibody capable of binding to a human CD40 antigen...
|
|
|
7361344 |
Co-administration of a thrombolytic and an-anti-CD18 antibody in stroke
A method for improving clinical outcome in focal ischemic stroke in a mammal by increasing cerebral blood flow and/or reducing infarct size is described which involves administering an effective...
|
|
|
7345046 |
Heteroaryl-fused pyrimidinyl compounds as anticancer agents
Heteroaryl-fused pyrimidinyl compounds, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the...
|
|
|
7338660 |
Methods of treating cancer and enhancing immune responses with antibodies that bind CD40
The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also...
|
|
|
7323171 |
Methods of treating skin conditions using inhibitors of the CD2/LFA-3 interaction
Methods of using inhibitors of the CD2/LFA-3 interaction in treating skin conditions characterized by increased T cell activation and abnormal antigen presentation in the dermis and epidermis in...
|
|
|
7323170 |
Anti-CD80 antibodies
The present invention relates to the identification of macaque antibodies to human B7.1 and B7.2 by screening of phage display libraries or monkey heterohybridomas obtained using B lymphocytes from...
|
|
|
7321026 |
Framework-patched immunoglobulins
Framework (FR)-patching is a novel approach to modify immunoglobulin for reducing potential immunogenicity without significant alterations in specificity and affinity. Unlike previous described...
|
|
|
7311910 |
Methods for treating cancer and infectious disease by blocking CTLA4-B7 interactions
The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing...
|
|
|
7309489 |
Mouse CD40 ligand-specific antibodies and hybridomas
There is disclosed a polypeptide (CD40-L) and DNA sequences, vectors and transformed host cells useful in providing CD40-L polypeptides. More particularly, this invention provides isolated human...
|
|
|
7306800 |
Treatment of autoimmune disorders with antibodies to costimulating polypeptide of T cells
A polypeptide (8F4 molecule) with a T-cell costimulating biological activity is disclosed, as well as monoclonal antibodies against the 8F4 molecule and hybridoma cells which produce the monoclonal...
|
|
|
7291331 |
Methods of treating OX40 medicated recall immune responses
T cell memory can persist in the absence of antigen. However, some memory cells by default are subject to signals accompanying periodic antigen exposure. OX40 is essential to the extent and...
|
|
|
7288252 |
Methods of therapy for B-cell malignancies using antagonist anti-CD40 antibodies
Methods of therapy for B-cell malignancies are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment...
|
|
|
7288251 |
Antibodies to CD40
The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also...
|
|
|
7264806 |
Modified anti-CD52 antibody
The present invention provides for modified forms of anti-CD52 antibodies with reduced numbers of potential T-cell epitopes that are expected to display decreased immunogenicity.
|
|
|
7259247 |
Anti-human T-cell costimulating polypeptide monoclonal antibodies
A polypeptide (8F4 molecule) with a T-cell costimulating biological activity is disclosed, as well as monoclonal antibodies against said 8F4 molecule and hybridoma cells which produce the...
|
|
|
7255854 |
Use of lymphotoxin-β receptor blocking agents for the treatment of antibody mediated immunological diseases
Compositions and methods comprising “lymphotoxin-β receptor blocking agents” which block lymphotoxin-β receptor signaling and are useful for altering immunological diseases, and particularly...
|
|
|
7250167 |
Method of treatment with anti-CD2 antibody LO-CD2b
A monoclonal antibody which binds to baboon and human CD2, and in particular LO-CD2b antibody. The antibody may be employed to prevent and inhibit an immune response in human patients, such as when...
|
|
|
7232567 |
Anti-CCR1 antibodies and methods of use thereof
The present invention relates to an antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 1 (CCR1) or a portion of the receptor and blocks binding...
|
|
|
7223395 |
Blocking leukocyte emigration and inflammation by interfering with CD99/HEC2
The present invention provides methods and compositions for modulating transendothelial migration (TEM) of leukocytes. In particular, inhibition of TEM can provide a potent therapeutic approach to...
|
|
|
7220412 |
Method of preparing an undifferentiated cell
Disclosed is a method of preparing an undifferentiated cell. The method includes contacting a more committed cell with an agent that causes the more committed cell to retrodifferentiate into an...
|
|
|
7211257 |
Methods for inducing apoptosis in ovarian carcinoma cells using an anti-regeneration and tolerance factor antibody
The present invention is directed to compositions and methods to modulate inflammatory and immune responses in a subject, which includes immune activation and inhibiting inflammatory responses, by...
|
|
|
7196175 |
Antibodies to JTT-1 protein and cells secreting such antibodies
Novel cell surface molecules recognized by monoclonal antibodies against a cell surface molecule of lymphocytic cells that play an important role in autoimmune diseases and allergic diseases have...
|
|
|
7192585 |
CD80 specific antibodies
The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and...
|
|
|
7183386 |
Feline immunoglobulin E proteins and compositions thereof
The invention relates to: nucleic acid molecules encoding the light chain and heavy chain of feline immunoglobulin E (IgE), including species-specific regions of feline IgE; proteins encoded by the...
|
|
|
7175847 |
Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and...
|
|
|
7172759 |
Induction of cytotoxic T lymphocyte responses using anti-CD40 antibodies
Disclosed are methods of inducing maturation of antigen presenting cells and cytotoxic T lymphocyte responses utilizing agonist anti-CD40 antibodies that do not block the binding of CD40L to CD40.
|
|
|
7169389 |
Human CD154 binding molecules and treatment methods
A CD154 binding molecule, in particular an antibody to human CD154, especially a human antibody to human CD154 is provided, wherein the CDRs of the heavy chain and light chain have amino acid...
|
|
|
7166283 |
Methods of treating an inflammatory disorder and prohibiting proliferation, cytokine production, and signal transduction with antibody against costimulatory signal transduction molecule AILIM
Immunization of human antibody-producing transgenic mice, which have been created using genetic engineering techniques, with AILIM molecule as an antigen resulted in various human monoclonal...
|
|
|
7157086 |
Treatment for inflammatory bowel disease with α4-specific antibodies
The present invention disclosed recombinant anti-VLA-4 antibody molecules, including humanized recombinant anti-VLA-4 antibody molecules. These antibodies are useful in the treatment of specific...
|
|
|
7153508 |
Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and...
|
|
|
7147851 |
Humanized immunoglobulin reactive with α4β7 integrin
The present invention relates to humanized immunoglobulins having binding specificity for α4β7 integrin, comprising an antigen binding region of nonhuman origin (e.g., rodent) and at least a...
|
|
|
7138243 |
NTB-A, a surface molecule involved in natural killer cells activity
The present invention relates to a novel protein, termed NTB-A, nucleic acid molecules encoding the same and uses thereof. The invention also relates to methods of regulating Natural Killer cells...
|
|
|
7132099 |
Methods of modulating T lymphocyte costimulation with an antibody to an 8F4 polypeptide
A polypeptide (8F4 molecule) with a T-cell costimulating biological activity is disclosed, as well as monoclonal antibodies against said 8F4 molecule and hybridoma cells which produce the...
|
|
|
7125551 |
Methods for treatment of asthmatic disorders using a monoclonal antibody to 8F4 polypeptide
The present invention relates to methods and compositions for the prevention and treatment and prevention of immune system disorders, including cancer, AIDS, asthmatic disorders, autoimmune...
|
|
|
7122187 |
Treating autoimmune diseases with humanized anti-CD40L antibody
The present invention is directed to humanized antibodies which bind human gp39 and their use as therapeutic agents. These humanized antibodies are especially useful for treatment of autoimmune...
|
|
|
7118743 |
Bispecific molecules cross-linking ITIM and ITAM for therapy
The invention includes bispecific molecules capable of cross-linking ITAM and ITIM receptors on a cell in order to inhibit cell activation, as well as gene therapy approaches using nucleotides...
|
|
|
7109306 |
Antibodies to human oncogene induced secreted protein I
The present invention relates to a novel protein, the Human Oncogene Induced Secreted Protein I (“HOIPS I”) protein. In particular, isolated nucleic acid molecules are provided encoding the...
|
|
|
7101550 |
PD-1, a receptor for B7-4, and uses therefor
The invention identifies PD-1 as a receptor for B7-4. B7-4 can inhibit immune cell activation upon binding to an inhibitory receptor on an immune cell. Accordingly, the invention provides agents...
|
|
|
7097837 |
Synthetic vaccine agents
The present invention provides for novel immungens that are comprised of an activated polyhydroxypolymer backbone to which is attached 2 separate antigenic determinants. The 1st antigenic...
|
|
|
7094404 |
Method for treating malignancy and autoimmune disorders in humans using tac antibodies
The present invention relates to a method for treating conditions associated with elevated levels of Tac-positive cells, including malignancy and autoimmune disorders and for preventing allograft...
|
|
|
7094402 |
Antibodies to human interleukin-11 receptor
Polynucleotides encoding the human IL-11 receptor and fragments thereof are disclosed. IL-11 receptor proteins, methods for their production, antibodies to human IL-11 receptor, inhibitors of...
|
|
|
7090845 |
Diagnosis and treatment of hepatic disorders
The present invention encompasses methods and compositions useful in diagnosing and treating hepatic disorders, especially those characterized by inflammation. The method comprises administration...
|
|
|
7090841 |
Use of CD63 inhibitors
The invention provides a method of decreasing human immunodeficiency virus entry into cells, the method comprising decreasing levels of functional CD63 present with the human immunodeficiency virus...
|
|
|
7074403 |
Immunotherapy of autoimmune disorders using antibodies which target B-cells
Antibodies that bind with a B-cell antigen provide an effective means to treat autoimmune disorders. Antibodies and fragments, which may be conjugated or naked, are used alone or in multimodal...
|